Samsung Biologics Signs Contract for Immuno-Oncology Drug CDMO with Israeli Pharmaceutical Company

Providing 'One-Stop Service' from Cell Line Development to Production and IND Approval Support

[Asia Economy Reporter Kim Ji-hee] Samsung Biologics announced on the 2nd that it has signed a contract for contract development and manufacturing organization (CDMO) services for the immuno-oncology drug (substance name DSP502) of Israel's KAHR Medical. Under this contract, Samsung Biologics will cover the entire new drug development process, from cell line development of DSP502 to clinical-grade active pharmaceutical ingredient (DS) production, finished product manufacturing services, and support for clinical trial application (IND) approval.

KAHR Medical is a biopharmaceutical company specializing in fusion proteins, possessing multifunctional immune-enhancing protein (MIRP) technology that selectively targets tumors by linking cancer cells and T-cells.

Yaron Pereg, CEO of KAHR Medical, said, "The DSP502 immuno-oncology drug works by weakening the defense mechanisms of cancer cells while activating immune cell responses through a bispecific protein, thereby treating cancer cells. We are pleased to collaborate with Samsung Biologics, a leading CDMO company."

John Rim, President of Samsung Biologics, stated, "Through integrated CDMO services, we will enable our clients to focus on their specialized areas of discovering and researching new pharmaceuticals."

This content was produced with the assistance of AI translation services.